Wang MH - Search Results

1

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

Hu CY, Xu XM, Hong B, Wu ZG, Qian Y, Weng TH, Liu YZ, Tang TM, Wang MH, Yao HP. Hu CY, et al. Among authors: wang mh. Front Oncol. 2019 Dec 5;9:1377. doi: 10.3389/fonc.2019.01377. eCollection 2019. Front Oncol. 2019. PMID: 31867280 Free PMC article.

2

RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.

Suthe SR, Yao HP, Weng TH, Hu CY, Feng L, Wu ZG, Wang MH. Suthe SR, et al. Among authors: wang mh. Mol Cancer Ther. 2018 Dec;17(12):2654-2664. doi: 10.1158/1535-7163.MCT-18-0252. Epub 2018 Oct 1. Mol Cancer Ther. 2018. PMID: 30275241

3

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.

Weng TH, Yao MY, Xu XM, Hu CY, Yao SH, Liu YZ, Wu ZG, Tang TM, Fu PF, Wang MH, Yao HP. Weng TH, et al. Among authors: wang mh. Cancer Res Treat. 2020 Jul;52(3):973-986. doi: 10.4143/crt.2019.726. Epub 2020 Apr 22. Cancer Res Treat. 2020. PMID: 32324988 Free PMC article.

4

Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer.

Liu YZ, Han DT, Shi DR, Hong B, Qian Y, Wu ZG, Yao SH, Tang TM, Wang MH, Xu XM, Yao HP. Liu YZ, et al. Among authors: wang mh. World J Gastrointest Oncol. 2020 Nov 15;12(11):1216-1236. doi: 10.4251/wjgo.v12.i11.1216. World J Gastrointest Oncol. 2020. PMID: 33250957 Free PMC article.

5

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase.

Yao HP, Tong XM, Wang MH. Yao HP, et al. Among authors: wang mh. Ther Adv Med Oncol. 2021 Apr 3;13:17588359211006957. doi: 10.1177/17588359211006957. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33868463 Free PMC article. Review.

6

RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.

Xu XM, Wang D, Shen Q, Chen YQ, Wang MH. Xu XM, et al. Among authors: wang mh, wang d. Oncogene. 2004 Nov 4;23(52):8464-74. doi: 10.1038/sj.onc.1207907. Oncogene. 2004. PMID: 15378025

7

Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase.

Xu XM, Zhou YQ, Wang MH. Xu XM, et al. Among authors: wang mh. J Biol Chem. 2005 Jul 1;280(26):25087-94. doi: 10.1074/jbc.M414699200. Epub 2005 May 6. J Biol Chem. 2005. PMID: 15878878 Free article.

8

Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.

Wang MH, Yao HP, Zhou YQ. Wang MH, et al. Acta Pharmacol Sin. 2006 Jun;27(6):641-50. doi: 10.1111/j.1745-7254.2006.00361.x. Acta Pharmacol Sin. 2006. PMID: 16723080 Review.

9

Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.

Lu Y, Yao HP, Wang MH. Lu Y, et al. Among authors: wang mh. Cancer Lett. 2007 Nov 18;257(2):157-64. doi: 10.1016/j.canlet.2007.08.007. Epub 2007 Sep 21. Cancer Lett. 2007. PMID: 17889431 Review.

10

Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility.

Zhang K, Yao HP, Wang MH. Zhang K, et al. Among authors: wang mh. Carcinogenesis. 2008 Mar;29(3):552-9. doi: 10.1093/carcin/bgn003. Epub 2008 Jan 19. Carcinogenesis. 2008. PMID: 18204077

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,528 results

Search Page

Filters